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A B S T R A C T
To assess the proposed associations of the c.742-227G>A (rs2612091) polymorphism within the Enolase
Superfamily Member 1 gene (ENOSF1) and two variants in the adjacent Thymidylate Synthase gene (TYMS): the
5’VNTR 28bp-repeat (rs45445694) and 3’UTR 6bp-indel (rs11280056) with severe toxicity in fluoropyrimidine-
treated cancer patients, we performed an individual patient data meta-analysis. Only studies investigating all
three-abovementioned variants with fluoropyrimidine-related toxicities were considered for meta-analysis.
Associations were tested individually for each study using multivariate regression. Meta-analysis was performed
using a random-effects model. One-stage multivariate regressions including tests for independent SNP effects
were applied to investigate individual effects of the variants. Multivariate haplotype regression analyses were
performed on a pooled dataset to test multi-SNP effects. Of four studies including 2’067 patients, 1’912 were
eligible for meta-analysis. All variants were exclusively associated with severe hand-foot-syndrome (HFS) (TYMS
2R: OR=1.50, p=0.0002; TYMS 6bp-ins: OR=1.42 p= 0.0036; ENOSF1 c.742-227G: OR=1.64
p < 0.0001, per allele). We observed independent effects for ENOSF1 c.742-227G>A and the TYMS 28bp-
repeat: each toxicity-associated allele increased the risk for severe HFS (OR=1.32 per allele, p < 0.0001).
Patients homozygous for both variants were at the 3-fold higher risk for severe HFS compared to wild-type
patients. Our results confirm an essential role for ENOSF1 c.742-227G and TYMS 2R-alleles in the development
of fluoropyrimidine-related HFS. This suggests an important function of these genes in the development of severe
HFS. Furthermore, these variants might help stratify patients in studies investigating measures of HFS preven-
tion.
1. Introduction
The two fluoropyrimidines (FP) 5-fluorouracil (5-FU) and the oral
prodrug capecitabine (Cp) are widely used anti-cancer drugs. Several
enzymatic steps are involved in their conversion to the main cytotoxic
compound 5-fluoro-deoxyuridine monophosphate, which results in the
inhibition of thymidylate synthase (TS) [1]. This inhibition leads to a
nucleotide imbalance, and subsequently to cell death. Due to this rather
unspecific mode of action, severe adverse effects are frequent and still
present a major concern in FP-based chemotherapies [2]. Interestingly,
the toxicity profiles of Cp and 5-FU differ considerably. Patients re-
ceiving Cp-based treatments are less likely to experience stomatitis and
neutropenia, but are at 3-fold higher risk for developing severe hand-
foot syndrome (HFS) [3]. A recently published phase three clinical trial
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using Cp in patients with biliary tract cancer reported severe HFS as the
most common toxicity (20 % frequency of grade 3 HFS). Furthermore,
this study reported that around 5 % of the patients discontinued
treatment exclusively due to HFS [4].
It is well established that the rate of degradation of 5-FU plays an
important role in the development of FP-induced toxicity. Specifically,
a reduced activity in the first and rate-limiting enzyme of the pyr-
imidine catabolic pathway, dihydropyrimidine dehydrogenase (DPD),
increases the risk of developing severe FP toxicity through an accu-
mulation of cytotoxic metabolites [5]. A recent prospective study
showed that pre-therapeutic screening of deleterious DPD gene (DPYD)
variants conferring reduced activity or complete enzyme deficiency is
clinically useful for reducing the occurrence of severe toxicities in FP-
treated patients [6]. Nevertheless, a majority of toxic effects remains
unexplained.
The gene encoding for TS (TYMS) has been extensively investigated
to assess potential biomarkers for FP treatment safety and effectiveness.
Two variants in TYMS, the 5′UTR tandem 28bp-repeat (5′VNTR)
(rs45445694) and the 3′UTR 6bp-indel (rs11280056), have been in-
vestigated by multiple groups [7]. Indeed, recent studies suggest a role
for these variants in the development of FP-related toxicities. Two
meta-analyses reported that patients carrying two 28bp repeats (2R)
instead of three (3R) in the TYMS 5′ UTR have a higher toxicity risk
[8,9]. Similarly, the TYMS 3′UTR 6bp-ins was also associated with in-
creased FP-related toxicity in a meta-analysis [9]. However, the modest
size of the effect of both of these variants did not support their clinical
implementation as biomarkers for toxicity risk prediction.
A recent study reported that the G allele of a novel variant in the
Enolase Superfamily Member 1 gene (ENOSF1), c.742-227G>A
(rs2612091), which is in partial genetic linkage with the TYMS 6bp-
indel and TYMS 28bp-repeat, was associated with global Cp-induced
toxicity, and in particular with HFS [10]. Additionally, this variant
seemed to explain the previously reported associations with the TYMS
6bp-ins and the TYMS 28bp 2R-allele [10]. This association of ENOSF1
c.742-227G>A with HFS could be replicated, and another study fur-
ther reported an association with overall survival (OS) and gastro-
intestinal toxicities [11,12]. The role of ENOSF1 in FP-metabolism or
mechanism of action is still not fully elucidated.
ENOSF1 was first described as reverse Thymidylate Synthase (rTS)
and a TYMS antisense gene [13]. The ENOSF1 and TYMS genes partially
overlap on chromosome 18 and are transcribed in opposite directions.
So far, three ENOSF1 isoforms have been described. One of them was
identified as a L-fuconate dehydratase. None of the isoforms showed a
metabolic function in 5-FU metabolism [14]. However, in vitro studies
suggested that ENOSF1 might be involved in the regulation of TYMS at
the protein and the RNA level and thus affect 5-FU treatment as a TYMS
regulator [15]. In order to evaluate the roles of the partially linked
variants: ENOSF1 c.742-227G>A, TYMS 6bp-indel, and TYMS 28bp-
repeat in the safety of FP-chemotherapy, we performed an individual
patient data (IPD) level meta-analysis of all available studies in-
vestigating these three variants in relation to adverse effects from FP-
chemotherapy. In addition, we genotyped the same candidate variants
in our own cohort consisting of 144 Cp-treated and of 403 5-FU-treated
patients.
2. Methods
2.1. Patients and sample collection
Between 2006 and 2013, blood samples of 547 consenting FP-
treated patients were collected at the Bern University Hospital
(Switzerland) and the Cantonal Hospital St. Gallen (Switzerland) de-
scribed previously in more detail [16,17]. All 547 patients provided
signed informed consent. Except for 15 subjects, all patients were of
self-declared Caucasian origin. Patient characteristics, chemotherapies,
and FP-associated toxicities within the first two cycles of chemotherapy
were recorded and graded according to the Common Terminology
Criteria for Adverse Events (CTCAE) v3.0 [18]. One patient had to be
excluded from the initial cohort due potential confusion of sample
identity. This cohort is referred as Hamzic et al. in the meta-analysis.
2.2. DNA sequencing and genotyping
Genomic DNA was extracted from EDTA blood samples as described
previously [16]. For genotyping of candidate polymorphism ENOSF1
c.742-227G>A (rs2612091), a validated TaqMan single nucleotide
polymorphism (SNP) genotyping assay (Thermo Fisher Scientific, assay
C__15908768_10) and a 7500 fast real-time polymerase chain reaction
(PCR) system (Thermo Fisher Scientific) were used. To determine the
variable number of tandem repeats in TYMS, the 5′UTR promoter re-
gion was amplified (primers: forward 5′-GTGGCTCCTGCGTTTCC
CCC-3′, reverse 5′-GCTCCGAGCCGGCCACAGGCATG-3′) using a GC-
rich PCR System (Roche Applied Science). The amplification resulted in
an amplicon size of 242 bp (3 repeats – 3R) and 214 bp (2 repeats – 2R),
respectively. PCR reactions were performed in GeneAmp 9800 Fast
Thermal Cyclers or GeneAmp 9700 Thermal Cyclers (Thermo Fisher
Scientific) with an initial denaturation step of 3min at 96 °C, 45 cycles
of 30 s at 96 °C, 30 s at 60 °C, and 45 s at 72 °C, followed by a final
extension step of 10min at 72 °C. To distinguish 2R and 3R genotypes,
amplified fragments were separated on a 1.5 % agarose gel. For the
analysis of the 6 bp ins-del polymorphism (c.*447_452del), a fragment
of the 3′UTR was amplified using a fluorescently labeled primer (for-
ward 5′-FAM−CCACGTACTTATAAAGAAGGTTGGTG-3′, reverse
5′-CAGAATGAACAAAGCGTGGACGAAT-3′). Amplifications were per-
formed using the QIAGEN Multiplex PCR kit (Qiagen) and the same
instrumentation as described for the TYMS promoter region. PCR re-
actions started with an initial denaturation step of 15min at 95 °C,
followed by 22 cycles of 30 s at 94 °C, 1min 30 s at 56 °C and 1min at
72 °C, and a final extension step of 10min at 72 °C. A mixture of 0.55 μl
GeneScan LIZ 600 Size Standard (Thermo Fisher Scientific) and
10.45 μl Hi-Di formamide (Thermo Fisher Scientific) was added to 1 μl
of PCR product and denatured for 3min at 95 °C. Denatured products
were subsequently resolved on an ABI Prism 3130xl Genetic Analyzer
(Thermo Fisher Scientific) and genotypes were determined using the
GeneMapper software v.4.0 (Thermo Fisher Scientific).
2.3. Study inclusion and data gathering
For this meta-analysis we focused on published studies, which in-
vestigated the effects of ENOSF1 c.742-227G>A (rs2612091), TYMS
6bp-indel (rs11280056), and TYMS 28bp-repeat (rs45445694) on FP-
related toxicities. The criteria for inclusion were (i) that the study has
genotyped all three candidate variants and (ii) investigated them for
association with severe FP-related toxicities. Furthermore, all studies
had to be conducted according to the Helsinki Declaration and in-
dividual toxicities had to be graded according CTCAE v3 or v4. Only
prospectively collected cohorts were considered. Literature search was
last conducted on April 11 2019. We used the search term “ENOSF1
AND TYMS AND (Fluorouracil OR 5-FU OR Capecitabine)” on Pubmed
(https://www.ncbi.nlm.nih.gov/pubmed/) and Embase (https://www.
embase.com/#search). In total, the search yielded 17 hits
(Supplementary Fig. 1). Since rs2612091 in ENOSF1 was the most re-
cently reported variant, it was the limiting factor for study inclusion.
We performed additional searches with the keywords “ENOSF1” and
“rs2612091” used separately, which yielded 69 hits in total. However,
this search did not reveal in any additional studies meeting the inclu-
sion criteria. In total, three studies met the criteria to be included in our
meta-analysis. We contacted the authors of these studies, who all
agreed to participate in this analysis [10–12]. The different study co-
horts are referred to as follows: Rosmarin et al. [10], Meulendijks et al.
[12], Garcia-Gonzalez et al. [11], and Hamzic et al. (our cohort). We
collected individual level data on genotypes for rs2612091,
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rs11280056, rs45445694, age, sex, type of cancer, tumor stage, treat-
ment setting, regimen including concomitant chemotherapy, number of
treatment cycles, DPYD genotypes (c. 1905+1G>A (rs3918290,
DPYD*2A), c. 1679T>G (rs55886062, DPYD*13), c. 2846A>T
(rs67376798) and c.1129-5923C>A (rs75017182, c.1236G>A/
HapB3)), and individual FP-related toxicities. All studies provided in-
dividual toxicity levels, except from Meulendijks et al. where data for
each individual patient was only available in a pre-coded format, i.e.
categorized into severe grade ≥ 3 or ≤ 2 toxicities. The authors of
Garcia-Gonzalez et al. provided unpublished data from 81 additional
patients of their study, leading to an extended cohort of 320 patients.
Only patients with complete genetic data were included into the ana-
lyses. This meta-analysis does not include new human data that requires
ethical approval. All included cohorts were collected in accordance
with the Declaration of Helsinki (10–12,16,17).
2.4. Association testing and meta-analysis
For this meta-analysis, we chose a two-stage approach. In the first
stage, each study was tested individually for association of genetic
variants with severe FP-induced toxicity (grade ≥ 3) using multivariate
logistic regression and odds ratios as summary measure. Sex, age, 5-FU/
Cp, and DPYD risk variant carrier status were included as co-factors for
every cohort. DPYD risk variant carrier status was coded with a binary
variable (‘risk’), where carriers of one of the four clinically relevant
DPD dysfunctional variants (c.1905+1G>A (rs3918290),
c.1679T>G (rs55886062), c.2846A> T (rs67376798) and c.1129-
5923C>A (rs75017182, c.1236G> A/HapB3) were classified as ‘risk
variant carrier’ and all others as’ non-carriers’. Furthermore, con-
comitant chemotherapy was included as co-factor depending on their
association with severe overall toxicity in the individual cohort. Overall
toxicity was defined as the highest toxicity grade observed in any
toxicity category in any cycle. All individual toxicity types were tested
using the same multivariate regression model. Publication bias was
assessed for all investigated individual outcomes by funnel plots and
Egger’s test. Due to the different therapy schemes and duration of
toxicity recording, we performed the meta-analysis using the
DerSimonian-Laird random-effects model with the R-package “metafor”
[19,20]. Statistical heterogeneity was assessed with I2-statistic and
Cochrane’s Q-test. All variants were tested assuming an additive allele
model. Multivariate regression including all variants in the pooled da-
taset was performed in one stage with the “rms” R-package. For one-
stage analyses of the pooled dataset, we introduced an additional ca-
tegorical co-variable into the model in order to account for cohort-de-
pendent effects. Furthermore, we included every concomitant che-
motherapy, which was significantly associated in the individual studies
with overall toxicity (‘cisplatin, ‘oxaliplatin’ and ‘bevacizumab’) as co-
variables into the one-stage regression. In order to analyze independent
effects of the investigated candidate variants, we performed multi-
variate analysis using the “–independent-effects”- function im-
plemented in PLINK version v1.07 on the pooled dataset in one-stage
including the abovementioned covariates. This function compares al-
leles that have a similar haplotypic background in order to find in-
dependent SNP effects. A cut-off p-value of p < 0.05 was chosen, and
no adjustment for multiple testing was performed due to significant
linkage among all three candidate variants. The PRISMA-IPD checklist
was used as guideline for the writing of the manuscript [21].
2.5. Post-hoc analysis
In order to test the effect of the TYMS variants independent of the
ENOSF1 c.742-227G>A genotype in the pooled dataset, a post-hoc
analysis was performed including only patients homozygous for the
ENOSF1 c.742-227A allele (n= 567), using the same multivariate re-
gression as mentioned above.
2.6. Haplotype analysis
For haplotype inference, we used two functions of the hap.stats
package in R, which allows for ambiguous haplotypes where linkage is
not complete [22–24]. The posterior probabilities are used to compute
the score with the “haplo.score”-function and are used as weights for
the regression coefficient in the “haplo.glm” function-based analysis.
The merged dataset (n=1’912) was used for this analysis, which was
performed in one stage as mentioned above in order to increase the
power for rare haplotypes. Genetic linkage between the three variants
was calculated with the “genetics” package in R.
2.7. Allele-score analysis
Analyses using an allele-score combining genotypes of TYMS 28bp-
repeat and ENOSF1 c.742-227A>G were performed based on a pooled
dataset including individual patient data of all study cohorts
(n= 1’912). The allele-score of a patient was calculated as the total
number of toxicity-associated alleles across the two variants. For each
toxicity associated allele copy at any of the two loci, the score increases
by 1. For example, a patient heterozygous for a toxicity-associated al-
lele for one of the variants received a score of one. Patients homozygous
for all of the toxicity-associated alleles at both loci received the max-
imum score of four, whereas patients carrying no toxicity-associated
allele received the minimum score of zero.
3. Results
3.1. Study inclusion and characteristics
We identified three studies in the literature search, which in-
vestigated the effects of ENOSF1 c.742-227G>A (rs2612091), TYMS
6bp-indel (rs11280056), and TYMS 28bp-repeat (rs45445694) in rela-
tion to FP-chemotherapies and were suitable for inclusion in the meta-
analysis (Table 1) search results and strategy are described in Supple-
mentary Fig. 1. Only one study investigating ENOSF1 c.742-227G>A
with FP-related toxicities in 62 Cp-treated patients was not included
into this analysis, since it did not include any of the TYMS variants [25].
From all included studies, we received individual patient data. Toxicity
data from the study of Meulendijks et al. was provided pre-coded for
each individual patient, i.e. categorized into in severe grade ≥ 3 and
grade ≤ 2 toxicities. In total, combined with the unpublished data from
our own cohort referred to as Hamzic et al., we included data from four
studies and 2’067 FP-treated patients. Only patients with no missing
genotypes for any of the TYMS, ENOSF1, and DPYD loci were included
in the analyses, which led to the exclusion of 154 patients. One addi-
tional patient was excluded due potential sample mix-up. Two in-
dividual patients were observed to carry a very rare TYMS 28bp 4R
allele. In order to simplify the analysis, these patients were also clas-
sified as carriers of the 3R allele in this study.
Of the remaining 1’912 patients included in the analysis, 1’511 were
treated with Cp mono- or combination therapy, whereas the remaining
402 were treated with infusional 5-FU mono- or combination che-
motherapy. We observed a high heterogeneity in the frequency of the
observed toxicity types among the studies, most likely due to differ-
ences in therapy schemes and number of cycles considered for toxicity
recording (Table 1).
3.2. Meta-analysis
The only variant associated with overall toxicity was the TYMS 6bp-
ins (OR=1.21 p=0.0215), where carriers of the 6bp-ins allele ex-
perienced higher overall toxicity rates (20.3 % of del/del-carriers vs.
28.3 % of ins/del carriers vs. 30.3 % ins/ins-carriers; Supplementary
Fig. 2). No significant publication bias was observed for TYMS 6bp-
indel and overall toxicity (Egger’s test p= 0.15). However, for the
S. Hamzic, et al. Pharmacological Research 152 (2020) 104594
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other two variants, we observed significant publication bias with
overall toxicity (TYMS 28bp-repeat and ENOSF1 c.742-227G>A,
Egger’s test: p= 0.01 and p < 0.01, respectively). This result was
driven by the study of Rosmarin et al., which reported the highest
frequency of severe HFS for their cohort (Table 1). When excluding this
study, no significant association of TYMS 6bp-indel with overall toxicity
was observed (Supplementary Fig. 2). All three variants were sig-
nificantly associated with severe (grade 3) HFS (TYMS 28bp 2R-allele:
OR=1.50, p= 0.0002; TYMS 6bp-ins: OR=1.41 p=0.0036;
ENOSF1 c.742-227G: OR=1.64 p < 0.0001; Fig. 1). When excluding
the study of Rosmarin et al. from the analysis, all three variants showed
ORs of similar magnitudes and the TYMS 28bp 2R-variant (OR=1.71,
p=0.0287) and TYMS 6bp-ins (OR=1.81, p=0.0423) remained
significantly associated with severe HFS (ENOSF1 c.742-227G:
OR=1.58 p=0.0604). No significant study heterogeneity and no
publication bias was observed with HFS as an outcome (Fig. 1, Sup-
plementary Fig. 3). Individual frequencies of severe HFS for each in-
dividual cohort are reported in the Supplementary Table 1. No sig-
nificant associations with any other individual toxicity type was
detected (Supplementary Fig. 2).
In the multivariate logistic regression of the pooled dataset
(n= 1’912) including all three loci in the regression model, only
ENOSF1 c.742-227G>A remained significantly associated with severe
HFS (TYMS 28bp 2R-allele: p= 0.2603, OR: 1.17 [0.89–1.52]; TYMS
6bp-ins: p= 0.6336, OR 1.07 [0.80–1.43]; ENOSF1 c.742-227G:
p=0.0176, OR: 1.45 [1.07–1.97]). However, when we performed
multivariate analyses applying the “–independent-effects”- function
implemented in PLINK version v1.07, we observed significant in-
dependent effects for the TYMS 28bp 2R- and ENOSF1 c.742-227G-al-
leles (TYMS 28bp 2R-allele: poverall = 0.0439; ENOSF1 c.742-227G:
poverall = 0.0015). No statistically significant independent effect could
be observed for the TYMS 6bp-ins (TYMS 6bp-ins: poverall = 0.6280)
(Supplementary Table 2).
Based on this result, we carried out a post-hoc analysis for assessing
the individual associations of TYMS 2R and TYMS 6bp-ins with HFS-
toxicity excluding all patients carrying the ENOSF1 c.742-227G variant.
In this sub-cohort of patients, who are homozygous for the protective A-
allele of ENOSF1 c.742-227G>A (n=567), we observed a significant
increase in HFS for each 2R allele copy (OR: 1.82 95 %CI: [1.13–2.92],
p= 0.0132), and a non-significant increase for the TYMS 6bp-ins copy
(OR: 1.23 95 %CI: [0.78–1.92], p= 0.3723) in a multivariate logistic
regression analysis.
In summary, these results thus suggest independent effects for the
TYMS 28bp 2R-allele and for the ENOSF1 c.742-227G-allele, whereas,
the association of the TYMS 6bp-ins may be driven by the partial
linkage with the other two variants.
3.3. Haplotype analyses
We observed strong linkage between ENOSF1 c.742-227G>A and
TYMS 6bp-indel (D’=0.90-0.95, R2= 0.31-0.39), and moderate
linkage among these two alleles and the TYMS 28bp-repeat (ENOSF1
c.742-227G>A -TYMS 28bp-repeat; D’=0.58-0.74, R2 = 0.32-0.46
and TYMS 6bp-indel-TYMS 28bp-repeat; D’=0.43-0.61, R2 = 0.07-
0.14) in all cohorts (Supplementary Table 3).
The most frequent haplotype (H1: 36.7 %), which consists of all
toxicity-associated variants at the three loci, showed the strongest as-
sociation with increased HFS risk (Table 2). The second most frequent
haplotype carrying none of the toxicity-associated alleles (H2: 24.3 %)
was significantly associated with reduced HFS-toxicity risk as was
haplotype H3 (H3: 19.9 %) carrying only the 6bp-ins allele. Haplotypes
composed of TYMS 6bp-ins and the TYMS 2R or the ENOSF1 G-allele
(H4: 8.2 % and H6: 3.5 %) were associated with severe (grade 3) HFS,
when compared to the protective haplotype H2 (Haplo.GLM function).
No other haplotype with only one toxicity-associated allele was sig-
nificantly associated with increased severe (grade 3) HFS (H3: 19.9 %Ta
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and H5: 6.5 %, H7: 0.58 % and H8: 0.31 %). These results further
support the associations of ENOSF1 c.742-227 G and TYMS 2R-allele
with severe HFS, but not for the TYMS 6bp-ins allele.
3.4. Allele-score analysis
We used an additive allele-score to investigate the effect of multiple
allele carriers of ENOSF1 c.742-227G>A and TYMS 28bp-repeat on
the risk for developing severe grade 3 HFS in the pooled dataset
(n=1’912). We observed a 3-fold increased risk of severe HFS in pa-
tients homozygous for the two toxicity-associated alleles, compared to
patients carrying none of the two variants (frequency of severe HFS
18.4 % vs. 6.1 %) (Fig. 2a). A multivariate regression in the pooled
dataset showed a significant increase of severe HFS with increasing
allele-scores (OR: 1.32 95 %CI: [1.18–1.49], per allele, p < 0.0001). In
comparison, we observed a frequency of 17.3 % of severe HFS in DPYD
risk variant carriers and 12.3 % in non-carriers, respectively. The fre-
quency of patients homozygous for ENOSF1 G- and TYMS 2R-alleles
was 13.9 %, whereas the frequency of patients carrying none of the two
alleles was 19.0 % (Fig. 2a). The overall frequencies of severe HFS
(grade 3) according to the individual SNPs in the pooled dataset are
shown in Fig. 2b
4. Discussion
This is the first meta-analysis evaluating the role of the recently
reported ENOSF1 variant c.742-227G>A with FP-related toxicities.
We included all published studies, which investigated ENOSF1 c.742-
227G>A together with the TYMS 28bp-repeat and TYMS 6bp-indel
variants for association of this variant with fluoropyrimidine related
toxicities. Including individual patient data allowed us to apply the
same genetic- and toxicity models for each study, improving the com-
parability among studies in the meta-analysis.
Our results strongly support that ENOSF1 c.742-227G>A is an
important pharmacogenetic marker for FP-related HFS. Furthermore,
our findings are in line with previous studies reporting significant as-
sociations of TYMS 28bp 2R-allele and TYMS 6bp-ins with FP-related
toxicities [8,10]. To follow up on these associations, this study also
investigated if ENOSF1 c.742-227G>A is the underlying causal variant
for this association, i.e. if the associations of both TYMS variants were
solely a result of genetic linkage with ENOSF1 c.742-227G>A, as
previously suggested [10]. While the results from the multivariate re-
gression analysis including all variants support this hypothesis, our
analyses for independent SNP-effects performed in PLINK indicate in-
dependent effects for both ENOSF1 c.742-227G>A and the TYMS
28bp-repeat. The observation that the TYMS 28bp-repeat was not as-
sociated with HFS in the multivariate regression may have resulted
from a bias introduced by multi-collinearity among the presumably
Fig. 1. Forest plots of meta-analyses of ENOSF1 and TYMS polymorphisms (TYMS 28bp-repeat, TYMS 6bp-indel, and ENOSF1 c.742-227A>G) associated with
severe HFS (grade 3). (A) Including all studies (B) Meta-analysis with exclusion of the cohort from Rosmarin et al. The toxicity-associated alleles are shown in
brackets. The square-size is proportional to the contribution of each study to the association. Horizontal lines and overall diamond width represent the 95 % CI of
observed odds ratios (OR).
Table 2
Association of three-SNP haplotypes with severe (grade 3) HFS. OR: Odds Ratios, Toxicity associated candidate SNPs are in bold and underlined. Significant p-values
are in bold. Haplotypes were calculated using a multivariate additive model.
Haplotypes Haplo.Score Haplo.GLM
TYMS
28bp-repeat
TYMS
6bp-indel
ENOSF1
c.742-227A>G
Haplotype
Freq.
Hap-Score P-value Sim P-value P-value OR [95 % CI]
H1 2R Ins G 36.72 % 3.496 0.0005 0.0002 <0.0001 1.75 [1.31–2.35]
H2 3R Del A 24.31 % −3.102 0.0019 0.0017 Base Haplotype
H3 3R Ins A 19.92 % −2.514 0.0119 0.0119 0.766 0.96 [0.65–1.39]
H4 3R Ins G 8.20 % 1.565 0.1176 0.1177 <0.0001 2.26 [1.45–3.52]
H5 2R Del A 6.50 % −0.193 0.8467 0.8460 0.344 1.33 [0.74–2.38]
H6 2R Ins A 3.47 % 1.712 0.0868 0.0836 0.018 2.06 [1.12–3.79]
H7 3R Del G 0.58 % −0.796 0.4258 0.4393 0.644 0.63 [0.07–5.38]
H8 2R Del G 0.31 % −0.110 0.9123 0.8989 0.704 1.60 [0.14–17.9]
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independent variables in the model. In other words, the observed par-
tial genetic linkage among the variants, resulting in correlation of the
corresponding variables, may have masked the effect of the TYMS
28bp-repeat in this analysis. Finally, the independent effect of the TYMS
28bp 2R-allele is supported by its association with HFS in a post-hoc
analysis including only patients with identical ENOSF1 genotype
(c.742-227AA).
In contrast, our analyses (e.g. using the “–independent-effects”-
function implemented in PLINK or the haplotype analyses) provided no
indication that the observed associations of the TYMS 6bp-ins with
overall toxicity and HFS in the two-stage meta-analysis represent or tag
an additional independent genetic effect. The variant was also not
found to be significantly associated with HFS in the post-hoc analysis
excluding the ENOSF1 c.742-227 G effect. The association of TYMS 6bp-
ins with HFS observed in the meta-analysis can be caused through a
hitch-hiking effect with the ENOSF1 c.742-227G-allele - i.e. through the
strong linkage between the two loci (D’=0.90-0.95, R2 = 0.31-0.39).
Due to the linkage among the three variants, it is very difficult to
estimate the effect sizes of each individual SNP based on the current
data. At present, we may only conclude that there is a strong indication
for at least two independent genetic effects contributing to increased
FP-related HFS-risk. Furthermore, we cannot exclude the possibility
that the studied variants are tagging other, yet unknown causal var-
iants. Therefore, we assumed an additive model for the allele-score and
the haplotype analyses. The results confirmed that carriers of multiple
associated alleles were at higher risk for toxicity, compared to patients
with none or only one toxicity-associated allele. Our results are mostly
relevant for Cp-treated patients, since 5-FU-treated patients show a
much lower incidence of HFS [7]. Even though HFS is not a life-
threatening toxicity, a recent phase three clinical trial reported severe
HFS as a major factor leading to chemotherapy cessation upon patient’s
choice [4]. Cp chemotherapy may thus be generally improved if pa-
tients with a high risk of developing severe HFS could be identified
prior to starting therapy. Furthermore, there have been efforts to pre-
vent HFS in Cp treated patients: Several studies investigated using to-
pical urea/lactic acid, pyridoxine and cyclooxygenase-2 inhibitors for
HFS prevention in a meta-analysis with mixed results [26]. Another
recent study observed that patients following non-drug related ther-
apeutic measures developed significantly less HFS [27]. High-risk pa-
tients could also potentially benefit from infusional 5-FU therapy to
reduce the risk of severe HFS. We recommend genotyping ENOSF1
c.742-227A>G and TYMS 28-bp repeat in upcoming studies in-
vestigating HFS preventing therapeutic measures for better stratifica-
tion of the patients potentially benefiting from such therapies. Fur-
thermore, the diagnostic potential of these candidate variants as
pharmacogenetic markers needs further evaluation in an independent
prospective study.
Our data suggest an important role of genetic variation in both
TYMS and ENOSF1 in the development of HFS. However, the under-
lying biological mechanisms inducing HFS are unknown, as well as the
biological function of ENOSF1. For ENOSF1, its role in 5-FU metabolism
is not known and a direct function of this gene in the metabolism of 5-
FU seems unlikely according to the study of Wicheleki et al. [14].
Nevertheless, several in-vitro experiments suggest that ENOSF1 may act
as a regulator of TYMS at the mRNA and the protein level [15]. How-
ever, further studies investigating the biological mechanism underlying
HFS and the function of ENOSF1 in FP-chemotherapy are needed.
Previously, ENOSF1 c.742-227G>A has been reported as an eQTL
for ENOSF1 but not for TYMS [10]. However, more recent data from
GTEx Portal (v7) indicated that ENOSF1 c.742-227G>A is an eQTL for
both, ENOSF1 and TYMS in many different tissues (Supplementary
Fig. 4). Therefore, a direct regulatory effect of the c.742-227G>A
variant on TYMS expression cannot be excluded. The TYMS 6bp-indel is
also an eQTL for both genes according GTEx Portal (v7) [28]. Inter-
estingly, the direction of the effect on mRNA levels is highly tissue
dependent for both variants. Additionally, ENOSF1 c.742-227G>A
and TYMS 6bp-indel are in significant linkage with many other var-
iants, which are strong eQTLs for both genes in various tissues (data not
shown). Taken together, these findings could explain some of the dis-
crepancies between in vitro and clinical association studies for TYMS
6bp-indel: It was suggested that the 6bp-deletion in the 3′UTR leads to
less stable mRNA and therefore less expression [29]. This is in contrast
to our and other meta-analyses, where the 6bp-ins was associated with
more FP-related toxicities, which suggest lower expression of TYMS for
the 6bp-ins allele [9]. However, our analysis suggests that the asso-
ciation of the TYMS 6bp-ins with toxicity is driven by genetic linkage
with the other two candidate variants and is likely not an independent
factor for the development of FP-related toxicities. Therefore, any direct
biological function of the TYMS 6bp-indel variant remains to be clar-
ified.
The current literature is more coherent with respect to our results
obtained for the TYMS 28bp-repeat: In line with our and other studies,
the 2R allele was associated with an increased risk of FP-related toxi-
cities [8,9,30,31]. Furthermore, the 2R allele has been associated with a
better response and less intra-tumoral expression of TYMS [31,32]. Less
expression of TYMS with the 2R-allele was also observed in-vitro [33]
[30,31]. All these data support that the TYMS 28bp repeat is an in-
dependent and direct causal factor affecting TYMS expression. How-
ever, the promoter structure in TYMS is actually more complicated:
There is also a G > C polymorphism found in this genomic region. The
Fig. 2. Two SNP allele-score and frequency of severe (grade 3) HFS according to the genotypes. (A) Two SNP allele score with ENOSF1 c.742-227A>G and TYMS
28bp-repeat in the total cohort (n=1’912). The score ranges from zero (no toxicity associated alleles) to four (homozygous for ENOSF1 c.742-227A>G and TYMS
28bp-repeat). (B) Frequencies of severe (grade 3) HFS according to individual genotypes of ENOSF1 and TYMS polymorphisms (TYMS 28bp-repeat, TYMS 6bp-indel,
and ENOSF1 c.742-227A>G) in the total cohort (n=1’912).
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C-allele was reported to disrupt a USF-1 binding site causing lower
TYMS expression in-vitro [34,35]. This SNP can be present in all 28bp-
repeat genotypes and a recent study showed that carriers of the 2R-
allele with the C-variant (2RC/2RC, 2RG/2RC, 3RC/2RC) were at
higher risk for Cp-related toxicities compared to non-carriers [36].
However, these variants are rather rare and the information of this sub-
classification was not available for all cohorts, which is a limitation of
this study. No data from GTEx Portal could be retrieved for TYMS 28bp-
repeat, most likely due to the complexity of genotyping this variant.
Another important limitation of this study is that haplotypes were in-
ferred by statistical methods, which can be problematic when only
partial linkage is present. This limitation could be overcome with
phased genotyping, which can be performed with new long-read se-
quencing technologies in order to determine haplotype structure un-
ambiguously in each individual patient sample by direct observation.
This would give more insights in the genetic structure underlying the
observed associations and may help identify potential other causal
variants. For example, a recent study reported additional novel variants
in the ENOSF1/TYMS region, which are associated with FP-induced
toxicities [37]. Therefore, it is possible that this genetic region harbors
further important markers for toxicity prediction. More studies in-
vestigating potential associations in this genetic region are thus needed.
5. Conclusion
In conclusion, our results strongly support the recently reported
independent association of the variant ENOSF1 c.742-227G>A variant
with severe HFS in FP-treated patients. Furthermore, the TYMS 28bp-
repeat was also independently associated with severe HFS. On the other
hand, the association of the TYMS 6bp-ins seems to be driven by genetic
linkage with the other two candidate variants. Based on the current
data, it is impossible to infer exact effect sizes of each individual variant
due to the considerable linkage among all three polymorphisms.
However, we may conclude that carriers of multiple copies of the as-
sociated variants are at higher risk for severe HFS as compared to pa-
tients carrying none or only one variant and that the studied genomic
region very likely harbors more than one independent genetic risk
factor for fluoropyrimidine-related HFS.
Genotyping these variants could help to improve patient stratifica-
tion in upcoming studies investigating HFS preventing therapeutic
measures. In order to verify the diagnostic potential of these variants,
prospective studies are needed.
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